Bloom Science Announces Poster Presentations at the 2024 American Epilepsy Society Annual Meeting
SAN DIEGO, Calif., December 5, 2024 – Bloom Science, Inc., a clinical-stage biotech company focused on the development of novel therapies for metabolic and neurological disorders, today announced that preclinical and clinical data from the company’s BL-001 program will be highlighted in three poster presentations at the 2024 American Epilepsy Society Annual Meeting. BL-001 is a first-in-class, orally delivered, Live Biotherapeutic Product (LBP) designed to replicate the therapeutic effects of the Ketogenic Diet being developed for the potential treatment of Dravet Syndrome and DEEs (Developmental and Epileptic Encephalopathies). The 2024 American Epilespy Society Annual Meeting is being held December 6-10 in Los Angeles, CA
One presentation will summarize results from the company’s Phase 1 clinical trial, a randomized, double-blind, placebo-controlled MAD (multiple ascending dose) study evaluating 28 days of daily treatment with an oral formulation of BL-001 in healthy subjects. A second presentation will highlight results from the company’s Phase 0 exploratory clinical study in healthy volunteers of BL-001 to assess strain kinetics and tolerability, followed by fecal microbiota transplant from volunteer-to-mice for seizure protection testing. A third presentation will focus on preclinical development data for BL-001 demonstrating anticonvulsive efficacy in multiple mouse models of epilepsy and in vitro modulation of neuronal hyperexcitation, neuroinflammation, and increased integrity of blood brain barrier and gut barrier.
Details of the presentations are as follows:
Poster #2.373:
Title: Safety, Tolerability, and Strain Kinetics of BL-001, an Orally Delivered Live Biotherapeutic Product, in a Phase 1 Study of Healthy Volunteers
Presenting Author: Louis Licamele, PhD, Chief Development Officer, Bloom Science
Date/Time: Sunday, December 8, 2024, 12-2:00 p.m. PST
Location: Exhibit Hall Los Angeles Convention Center
Poster #2.413:
Title: Reverse Translational Validation of Anti-Epileptic Effect of Prototype BL-001 in a Preclinical Seizure Model from a Phase 0 Trial in Healthy Volunteers
Presenting Author: Brent Nowinski, PhD, Scietnist, Bloom Science
Date/Time: Sunday, December 8, 2024, 12-2:00 p.m. PST
Location: Exhibit Hall Los Angeles Convention Center
Poster #2.414:
Title: Selection of Lead Candidate Bacteria for BL-001, a Live Biotherapeutic Product in Development for the Treatment of Neurological Indications
Presenting Author: Lisa Elmén, PhD, Sr Scientist and Andra Ionescu Tucker, PhD, Scientist, Bloom Science
Date/Time: Sunday, December 8, 2024, 12-2:00 p.m. PST
Location: Exhibit Hall Los Angeles Convention Center
About BL-001 and the Ketogenic Diet
BL-001 is a first-in-class, orally delivered, Live Biotherapeutic Product (LBP) being developed by Bloom Science. BL-001 is designed to replicate the therapeutic effects of the ketogenic diet. Preclinical data has demonstrated replication of the ketogenic diet therapeutic effect in epilepsy models and further demonstrated modulation of gamma aminobutyric acid (GABA) and other key bioenergetic pathways to suppress hyperexcitability which is a key driver in seizures.
The ketogenic diet was initially developed in 1921 to mimic fasting as a treatment for epilepsy. The ketogenic diet is a medical diet that is very-low in carbohydrates and high in fat used to treat epilepsy in children but there is accumulating clinical evidence that the diet is effective for weight loss, reversing metabolic dysfunction and treating mental illness. While the ketogenic diet has been shown to work quite well for patients, it can be an incredible challenge to maintain indefinitely.
About Bloom Science, Inc.
Bloom Science, Inc. is a clinical-stage biotech company focused on the development of novel first-in-class therapies for the treatment of metabolic and neurological disorders. Bloom’s research and development activities leverage its expertise in gut-brain axis biology, metabolism and the microbiome to develop innovative therapeutics designed to improve patients’ lives. Bloom’s clinical programs include BL-001, a first-in-class, orally delivered, Live Biotherapeutic Product (LBP) designed to replicate the therapeutic effects of the Ketogenic Diet. Bloom’s proprietary discovery platform, IrisRx™ enables a fundamentally different approach to developing medicines by harnessing our expanding insight into the Gut-Brain Axis to design and develop therapeutics that target novel biology with superior safety profiles. Bloom Science is advancing a deep pipeline of programs, focused in Obesity, Dravet syndrome and DEEs, Amyotrophic Lateral Sclerosis (ALS), and other neurodegenerative and cognitive disorders.